Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pfizer’s Eczema Drug Gains FDA Approval

XTALKS VITALS NEWS

FDA

The drug is a non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor, which is approved for use in patients over the age of two.

Share this!

December 16, 2016 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has approved Pfizer’s Eucrisa (crisaborole), a novel treatment for mild to moderate atopic dermatitis – also known as eczema. The drug is a non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor, which is approved for use in patients over the age of two.

“The approval of Eucrisa is great news for the children and adults suffering from mild to moderate eczema, a community that has not had a new prescription treatment for more than 10 years,” said Albert Bourla, Group President, Pfizer Innovative Health. “This is also an important milestone for Pfizer as we continue to build on our heritage in Inflammation and Immunology by offering innovative treatment options to patients who need them.”

According to Pfizer, almost 18 million people in the US have been diagnosed with eczema, 90 percent of whom have the mild to moderate form of the chronic condition. An overactive PDE-4 enzyme has been associated with an increase in eczema-associated symptoms.



While Eucrisa is the first and only drug of its kind to inhibit the PDE-4 enzyme, its mechanism of action has not been fully elucidated. Two randomized, controlled clinical trials involving 1,522 patients between the ages of two and 79 showed that Eucrisa was statistically significant in terms of efficacy, compared to the vehicle alone.

“I’m delighted to have a new option for my patients with mild to moderate atopic dermatitis,” said Dr. Amy Paller, Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, Northwestern University Feinberg School of Medicine, and a clinical trial investigator. “The results seen in these pivotal Phase 3 studies show the efficacy and safety of Eucrisa as a steroid-free treatment option for people as young as two living with mild to moderate atopic dermatitis.”

Pfizer acquired Eucrisa in May, after it bought-out California-based Anacor Pharmaceuticals. According to data and analytics company, GlobalData, the eczema market is expected to reach $7.3 billion by the year 2024.


Keywords: Eczema, FDA, Prescription Drug


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.